🧬 Aging Wiki

sarcopenia

Properties1
aliasesage-related muscle loss, age-associated muscle wasting, age-related muscle atrophy

9 min read

Sarcopenia

The age-associated loss of skeletal muscle mass, strength, and physical function. Distinct from cachexia (disease-driven wasting) and disuse atrophy (immobilization-driven), though they often co-exist. Recognized as a disease in its own right (ICD-10 M62.84; ICD-11 FB32.Y) 1, not merely a normal aging variant. A leading driver of frailty, falls, fractures, loss of independence, and all-cause mortality in older adults.

Diagnostic criteria — modern consensus

Three competing operational definitions are in current use; results are not perfectly interchangeable:

EWGSOP2 (European, 2019) — most-used in research

Hierarchical algorithm 2:

  1. Find — SARC-F questionnaire score ≥ 4 OR clinical suspicion
  2. Assess — Low muscle strength (handgrip dynamometry; chair-stand test) → “probable sarcopenia”
  3. Confirm — Low muscle quantity or quality (DXA, BIA, MRI/CT) → “confirmed sarcopenia”
  4. Severity — Low physical performance (gait speed ≤ 0.8 m/s, SPPB ≤ 8, TUG ≥ 20 s) → “severe sarcopenia”

EWGSOP2 explicitly leads with strength rather than mass — a 2019 reframing reflecting evidence that strength predicts adverse outcomes better than mass alone.

AWGS (Asian Working Group for Sarcopenia, 2019)

Similar three-step (case-finding → assessment → diagnosis) with population-adjusted cutpoints — Asian populations have lower mean muscle mass; using European cutpoints would over-diagnose.

FNIH (Foundation for the NIH, 2014)

Originally proposed for U.S. population. Different cutpoints for handgrip strength and ALM/BMI. Less common in current research.

Practical implication: sarcopenia prevalence estimates vary 5–25% in the same population depending on which criteria are applied. Always cite the specific definition.

Pathophysiology

Sarcopenia is a multi-mechanism phenotype; no single pathway accounts for it. Major contributors:

Muscle stem cell (satellite cell) dysfunction

  • Reduced satellite cell number and proliferative capacity with age — see stem-cell-exhaustion.
  • Impaired niche signaling (Wnt, Notch, GDF11/myostatin axis) further reduces regenerative response to injury.
  • Heterochronic parabiosis demonstrated that aged satellite cell dysfunction is driven largely by the systemic environment rather than irreversible cell-intrinsic defects: aged cells retain intrinsic proliferative capacity, but the old systemic milieu suppresses Notch signalling required for activation 3. More recent work has refined and extended this view.

Anabolic resistance

  • Aged muscle requires a higher dose of leucine / amino acids to maximally stimulate protein synthesis (the “leucine threshold” rises with age).
  • Reduced post-prandial muscle protein synthesis response.
  • Blunted mTORC1 activation per unit anabolic stimulus.
  • Practical implication: protein RDA (0.8 g/kg/day) is insufficient for older adults — current consensus recommends 1.0–1.2 g/kg/day, more if frail. See protein-intake for the canonical evidence base (Bauer 2013 PROT-AGE consensus + Deutz 2014 ESPEN guidelines).

Mitochondrial dysfunction in muscle

  • Age-related decline in mitochondrial content and oxidative capacity in muscle — see mitochondrial-dysfunction.
  • mtDNA deletions accumulate, with mosaic deficiency creating “ragged red fiber” patches.
  • Impaired mitophagy contributes to dysfunctional mitochondria persistence.

Chronic inflammation

  • Elevated IL-6, TNF-α, and other SASP-aligned cytokines in aged serum — see chronic-inflammation (the “inflammaging” phenomenon).
  • Direct catabolic effects on muscle protein synthesis and via increased autophagy/UPS proteolysis.
  • Senescent cell accumulation in muscle (cellular-senescence) drives local inflammatory milieu.

Neurogenic component

  • Loss of motor neurons (~25% lost between ages 25 and 75 in some studies) and reduced motor unit number.
  • Re-innervation by surviving motor neurons creates larger, less efficient motor units.
  • Distinguishes sarcopenia partly from pure cachexia or disuse atrophy.
  • 15-PGDH gerozyme axis (Blau lab, Stanford): the prostaglandin-degrading enzyme 15-pgdh (HPGD) is elevated in aged skeletal muscle (myofibers + macrophages) and rises further with denervation, depleting muscle PGE2; pharmacological inhibition with sw033291 (or genetic Hpgd depletion) restores muscle mass, grip strength, and exercise capacity in aged mice via PGE2-EP4 → mitochondrial biogenesis + autophagy induction + TGF-β suppression + UPS suppression 4. Cross-tissue extension: 15-PGDH aggregates also define “target fibers” — histopathologic hallmarks of human neurogenic myopathies — and PGDHi restores neuromuscular junction integrity in aged + chronically denervated mice 5. This positions sarcopenia mechanistically as a gerozyme-driven phenotype; the IP estate (formerly Myoforte Therapeutics → now Epirium Bio) is the only known clinical-translation vehicle, though no registered PGDHi clinical trial existed as of 2026-05-23 (druggability tier 2, high-quality probe — see 15-pgdh).

Hormonal changes

  • Reduced testosterone (men), estrogen (women), GH/IGF-1 (both) — all anabolic for muscle.
  • Vitamin D deficiency strongly associated with sarcopenia; supplementation evidence is mixed.

Risk factors and prevalence

FactorEffect
AgeStrongest single predictor; ~1–2% muscle mass loss/year and ~1.5–5% strength loss/year after age 50 6
Female sexLower baseline mass + post-menopausal hormonal acceleration
Sedentary lifestyleDisuse compounds aging-related loss
Chronic disease (CHF, COPD, CKD, cancer)Cachexia overlays sarcopenia
Hospitalization / immobilizationAcute losses (~1 kg lean mass per 10 days bed rest in older adults) often not fully recovered
Inadequate protein intakeBelow 1.0 g/kg/day in older adults

Prevalence estimates (community-dwelling adults): 1–29% depending on criteria and population studied 7; ≥30% in long-term care populations; ≥50% in some chronic disease cohorts. The narrower range “~10–16%” sometimes quoted reflects stricter EWGSOP criteria in specific European community cohorts — always cite the specific definition when reporting prevalence.

Outcomes

Sarcopenia is associated with — and prospectively predicts — adverse outcomes independent of comorbidities:

  • Falls — 1.5–3Ă— risk
  • Fractures — particularly hip
  • Hospitalization — increased length of stay, post-discharge functional decline
  • Disability — loss of ADL/IADL independence
  • Mortality — 2–3Ă— all-cause mortality risk (varies by criteria + population)
  • Surgical outcomes — sarcopenia on pre-op CT associated with worse outcomes across multiple surgery types

Interventions

Evidence rank (strongest first):

Resistance training

The single most effective intervention. Even nonagenarians (up to age 96) in nursing homes showed meaningful strength gains (averaging 174% ± 31%) and increased muscle cross-sectional area after 8 weeks of high-intensity resistance training 8. Recommendations: 2–3 sessions/week, multi-joint compound movements, progressive overload. needs-replication — n=10 frail nursing-home residents in original study; results have been widely replicated across populations.

Adequate protein + leucine

See protein-intake for the canonical evidence base; key points:

  • Daily protein ≥ 1.0–1.2 g/kg (1.2–1.5 if frail or in recovery) — Bauer 2013 PROT-AGE + Deutz 2014 ESPEN consensus
  • Distribution matters — ~25–40 g per meal Ă— 3–4 meals appears more effective than skewed intake (Mamerow 2014)
  • Leucine ≥ 2.5–3 g/meal helps overcome anabolic resistance (Moore 2015 meta-regression: older adults require ~0.40 g/kg/meal vs ~0.24 g/kg/meal in young adults)
  • Whey protein has the strongest evidence base; plant proteins effective if total intake is adequate

Vitamin D

  • Replete (25-OH-D > 30 ng/mL) if deficient
  • Supplementation in non-deficient individuals: evidence weaker

Pharmacological (investigational)

AgentClassStatus
BimagrumabActRII receptor antagonistPhase 2 — increased lean mass; functional benefit less clear
Myostatin inhibitors (e.g., trevogrumab, tarazimab)Anti-myostatin antibodiesPhase 2/3 — modest functional improvement; effect on hard outcomes pending
SARMs (selective androgen receptor modulators)Androgen receptor agonistsInvestigational — efficacy + safety unsettled
Testosterone (men with low T)AndrogenModest mass gain; cardiovascular safety debate ongoing
Senolytics (fisetin, dasatinib + quercetin)Senescent cell clearancePreclinical evidence for muscle benefit; human sarcopenia-specific trial limited
15-pgdh inhibitors (PGDHi, e.g. sw033291)Gerozyme inhibition — restores tissue PGE2 to physiologic levelsPreclinical: aged-mouse muscle mass + strength + exercise performance restored; mechanism via PGE2-EP4 → ↑mitochondria, ↑autophagy, ↓TGF-β, ↓UPS 4; NMJ regeneration extension 5. IP held by Epirium Bio (formerly Myoforte) but no registered PGDHi trial as of 2026-05-23 (high-quality probe, not yet a clinical drug — druggability tier 2). Cancer-aging tradeoff caveat: 15-PGDH is a colon/lung tumor suppressor — see cancer-aging-tradeoffs

Diet patterns

Mediterranean diet associated with reduced sarcopenia incidence in observational cohorts. Causal evidence limited.

Hallmark mapping

Sarcopenia is a convergent integrative phenotype — multiple hallmarks-of-aging feed into it:

Limitations and gaps

  • Strength vs mass discordance — many older adults lose strength faster than mass (dynapenia); the optimal definition is not fully settled.
  • Imaging gold standard — DXA estimates of lean mass include non-muscle tissue; D3-creatine dilution gives more accurate true muscle mass but is research-only.
  • Outcomes definition — falls, fractures, mortality are downstream of many co-morbidities; isolating sarcopenia’s independent contribution is difficult. needs-replication
  • Treatment-effect heterogeneity — protein supplementation works much better when paired with resistance training; isolated nutritional interventions show smaller effects.

Footnotes

Footnotes

  1. cruz-jentoft-2019-ewgsop2-sarcopenia · doi:10.1093/ageing/afy169 · EWGSOP2 (Cruz-Jentoft et al. 2019) notes sarcopenia is “formally recognised as a muscle disease with an ICD-10-MC Diagnosis Code that can be used to bill for care in some countries” — the specific year of ICD-10 M62.84 adoption and ICD-11 FB32.Y are not confirmed in this source. unsourced for year “2016” and ICD-11 code ↩

  2. cruz-jentoft-2019-ewgsop2-sarcopenia · doi:10.1093/ageing/afy169 · Cruz-Jentoft AJ et al. · consensus statement · European Working Group on Sarcopenia in Older People 2 (EWGSOP2) · Age and Ageing 2019;48(1):16-31 · the 2019 reframed diagnostic algorithm (strength-led); Table 3 specifies cutpoints: grip strength <27 kg (men)/<16 kg (women); chair stand >15 s for 5 rises; gait speed ≤0.8 m/s; SPPB ≤8; TUG ≥20 s ↩

  3. conboy-2005-parabiosis-satellite-cells · doi:10.1038/nature03260 · Conboy IM et al. · in-vivo heterochronic parabiosis · Nature 2005;433:760-764 · young (2–3 mo) C57Bl/Ka-Ly5.2 (or β-actin-eGFP) mice paired with aged (19–26 mo) C57Bl/6 mice; n=3-6 pairs per condition; P<0.005; <0.1% GFP+ engraftment in regenerated aged muscle confirms resident-cell activation rather than circulating-cell engraftment · “the age-related decline of progenitor cell activity can be modulated by systemic factors that change with age”; mechanism is Notch signalling restoration; cells retain intrinsic proliferative capacity · model: mus-musculus ↩

  4. palla-2021-15pgdh-muscle-rejuvenation · doi:10.1126/science.abc8059 · PMID 33303683 · PMC7938328 · in-vivo · model: young C57BL/6 (2–4 mo) vs aged (>24 mo); SW033291 mg/kg dose not stated in paper; human vastus lateralis microarray data from Raue 2012 dataset · Palla AR… Blau HM · Science 371(6528):eabc8059 (2021) · verified 2026-05-23 against PMC7938328 ↩ ↩2

  5. bakooshli-2023-15pgdh-nmj-regeneration · doi:10.1126/scitranslmed.adg1485 · PMID 37820010 · PMC10763629 · in-vivo (sciatic crush + chronic denervation + aged mouse) + observational human IHC (target fibers in neurogenic myopathies) · Bakooshli MA… Blau HM · Sci Transl Med 15(717):eadg1485 (2023) ↩ ↩2

  6. cruz-jentoft-2019-ewgsop2-sarcopenia · doi:10.1093/ageing/afy169 · “Beyond the age of 50 years, loss of leg muscle mass (1–2% per year) and loss of strength (1.5–5% per year) have been reported” (p. 23, citing ref [129]) — these are reported figures from the literature, not primary data from this paper ↩

  7. cruz-jentoft-2014-sarcopenia-prevalence · doi:10.1093/ageing/afu115 · Cruz-Jentoft AJ et al. · systematic review · n=18 prevalence studies · Age and Ageing 2014;43(6):748-759 · community-dwelling prevalence: 1–29%; long-term care: 14–33%; acute hospital: 10% (one study only) · all studies used EWGSOP definition ↩

  8. doi:10.1001/jama.1990.03440220053029 · Fiatarone MA et al. · JAMA 1990;263(22):3029-3034 · n=10 frail nursing-home residents aged ~90 (up to 96) · 8 weeks high-intensity weight training · strength gains averaged 174% ± 31%; increased muscle cross-sectional area; improved walking speed · closed-access: results taken from PubMed abstract no-fulltext-access ↩

Graph View

Backlinks